Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14102198
Abstract: Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug and thereby limits the clinical application. In… read more here.
Keywords: bexarotene; prediction bexarotene; bioavailability; bex ... See more keywords